Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Glass dressing aims to heal diabetic foot ulcers faster

NCT ID NCT06403605

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a borate-based bioactive glass wound matrix (Mirragen) plus standard care against standard care alone for diabetic foot ulcers. 148 adults with diabetes and a foot ulcer were enrolled. The main goal was to see if the glass dressing helped more wounds close completely within 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mirragen Advanced Wound Matrix (borate-based bioactive glass)
What this could lead to
If successful, this could provide a new option to help diabetic foot ulcers heal faster and more completely.
What could go wrong
This is a completed trial, but results are not yet widely known. The device is already commercially available, so the benefit over standard care may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

148 people

The number who actually took part.

Started

Sep 2022

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects must be at least 18 years of age or older. 2. Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus. 3. At randomization subjects must have a target diabetic foot ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with a photographic planimetry app. 4. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit. 5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus. 6. The target ulcer must be full thickness on the foot or ankle that does not probe to bone. 7. Adequate circulation to the affected foot as documented by any of the following methods performed within 3 months of the first screening visit: 1. TCOM ≥30 mmHg 2. ABI between 0.7 and 1.3 3. PVR: Biphasic 4. TBI ˃0.6 5. As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle 8. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer. 9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to randomization. 10. The subject must consent to using the prescribed off-loading method for the duration of the study. 11. The subject must agree to attend the weekly study visits required by the protocol. 12. The subject must be willing and able to participate in the informed consent process. Exclusion Criteria: 1. A subject known to have a life expectancy of \< 6 months is excluded. 2. If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded. 3. Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence. 4. A potential subject cannot have an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy. 5. A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded. 6. The topical application of steroids to the ulcer surface within one month of initial screening is not permitted. 7. A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer. 8. If a subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% taken at or within 3 months of the initial screening visit he/she is excluded. 9. If a subject has a serum creatinine ≥ 3.0mg/dL within 6 months of randomization he/she is excluded. 10. The subject is excluded if the surface area measurement of the target ulcer has reduced in size by more than 30% in the 2 weeks prior to the initial screening during the 2-week screening phase: the 2 weeks from the initial screening visit (SV1) to the TV1/randomization visit during which time the subject received SOC. 11. A subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer is excluded. 12. Women who are pregnant or considering becoming pregnant within the next 6 months are excluded. 13. A potential subject with end stage renal disease requiring dialysis is excluded. 14. A subject who participated in a clinical trial involving treatment with an investigational product within the previous 30 days is excluded. 15. A subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments is excluded. 16. A subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit is excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic foot are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Casa Colina

    Pomona, California, 91769, United States

  • Center for Clincal Research

    San Francisco, California, 94115, United States

  • Doctor's Research Network

    South Miami, Florida, 33143, United States

  • Foot and Ankle Center of Illinois

    Springfield, Illinois, 62704, United States

  • Foot and Ankle Specialists of the Mid Atlantic

    Frederick, Maryland, 21703, United States

  • Foot and Ankle Specialists of the Mid Atlantic

    Salem, Virginia, 24153, United States

  • Gateway Clinical Trials

    O'Fallon, Illinois, 62269, United States

  • LA Foot and Ankle

    Los Angeles, California, 90010, United States

  • Lower Extremity Institute for Research and Therapy

    Youngstown, Ohio, 44512, United States

  • Mercy Medical Center

    Cedar Rapids, Iowa, 52403, United States

  • PULSE: Amputation Prevention Center, LLC

    El Paso, Texas, 79902, United States

  • Southernmost Foot and Ankle Specialists

    Homestead, Florida, 33030, United States

  • United Wound Healing P.S

    Auburn, Washington, 98092, United States

  • Wound Care Experts

    Las Vegas, Nevada, 89148, United States

  • Wound Centrics

    Corpus Christi, Texas, 78404, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.